Teva
Teva forges ahead with Mylan pursuit
May 6, 2015Sales and Marketing Mylan, Perrigo, Teva, generics
Teva has reinforced its commitment to buy Mylan despite previous rejection and only days after Mylan upped its own bid …
Perrigo bats away raised Mylan bid
April 30, 2015Sales and Marketing Mylan, Perrigo, Teva, Vigodman, merger
Perrigo has rejected an updated $34.1 billion takeover bid from Mylan, whilst Teva has also written an open letter in …
FDA waves through generic BMS antipsychotic
April 30, 2015Manufacturing and Production, Sales and Marketing Alembic, BMS, FDA, Hetero and Torrent Pharmaceuticals, Teva
The FDA has approved four generic versions of Bristol-Myers Squibb’s top selling Abilify, an atypical antipsychotic drug approved to treat …
M&A drama continues as Mylan rejects Teva
April 28, 2015Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers
Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …
Teva faces $512m fine in generic Provigil row
April 22, 2015Sales and Marketing Cephalon, Mylan, Teva, generic, modafinil, provigil
Teva has agreed to a record $512 million settlement in a ‘pay-to-delay’ row over generic versions of its drug Provigil. …
Teva moves to buy Mylan
April 21, 2015Research and Development, Sales and Marketing India, Mylan, Perrigo, Teva, US, Vigodman, generics, israel, merger
Israeli generics drug giant Teva has made an offer to buy its US rival Mylan for around $40.1 billion. The …
FDA approves generic Copaxone for multiple sclerosis
April 17, 2015Sales and Marketing FDA, Sandoz, Teva, glatiramer acetate injection, glatopa
The FDA has signed-off on the first generic version of Copaxone to treat people with relapsing forms of multiple sclerosis …
Teva bolsters neurology unit through Auspex deal
March 31, 2015Sales and Marketing CNS, SD-809, Teva, Tourette syndrome, auspex, deutetrabenazine, neurology
Teva is significantly enhancing its neurology business by acquiring US biopharma firm Auspex in a deal worth $3.5 billion. Teva …
Teva hires new business development head
March 25, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, timothy wright
Teva Pharmaceutical Industries has confirmed the appointment of Timothy Wright to its executive leadership team to head up business development, …
Teva and Ignyta shake hands in oncology deal
March 19, 2015Research and Development, Sales and Marketing CEP-32496, CEP-40125, Levact, RXDX-105, Teva, ignyta, oncology
Ignyta has acquired four oncology R&D assets from Israeli pharma generics giant Teva in a deal worth around $42 million. …
Teva to sell US manufacturing plant
March 4, 2015Manufacturing and Production, Sales and Marketing G&W Laboratories, Pennsylvania, Teva
Teva Pharmaceutical has announced that it has signed an agreement to sell a US manufacturing facility to G&W Laboratories. The …
US Supreme Court backs Teva in Copaxone patent case
January 28, 2015Sales and Marketing Copaxone, Momenta Pharmaceuticals, Mylan, Natco Pharma, Teva
Teva has won a US Supreme Court judgement allowing it to continue marketing its multiple sclerosis drug Copaxone without challenge …
Teva’s Nexium copycat approved in US
January 27, 2015Manufacturing and Production, Sales and Marketing AstraZeneca, Teva, esomeprazole, gerd, heart, nsaids
Teva has won approval for its copycat form of AstraZeneca’s big-selling heatburn drug Nexium, making it the first generic version …
New Teva chairman announced
November 28, 2014Manufacturing and Production, Sales and Marketing Phillip Frost, Teva, Yitzhak Peterburg, barer, generics, israel
Teva Pharmaceutical Industries has confirmed that Professor Yitzhak Peterburg is to serve as its new chairman from January. Peterburg who …
Teva to ditch R&D in cancer and women’s health
October 6, 2014Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, FDA, MS, R&D, Teva, cuts, generics
Teva will stop research into oncology and women’s health in order to cut costs and focus more on generics and …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
